Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Merck Sharp + Dohme Corp.

Zymeworks Inc.

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Shanghai Hansoh Biomedical Co., Ltd.

Changzhou Hansoh Pharmaceutical Co., Ltd.

Hua Ying

Weikang Tao

Hu Ge

Jinping Shi

Yifang Wang

Qiyue Hu

Laurence Fayadat-Dilman

Veronica Juan

Shireen S Khan

Tingting Li

Ling Zhang

Guimei Yang

Shaopeng Huang

Lei Zhang

Ling L Zhang

Xiaomin Zhang

Ting Zhang

Jianyan Xu

Eric Escobar Cabrera

Xiaoying Yang

Jiakang Sun

Genevieve Desjardins

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.

Antibody capable of binding to thymic stromal lymphopoietin and use thereof

Disclosed by the present invention are an anti-B7H3 antibody-exatecan analog conjugate, a preparation method therefor and an anti-tumor medicinal use thereof.

Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof

Murine, chimeric or humanized anti-Abeta antibody having a specific CDR region, an antigen-binding fragment thereof, a pharmaceutical composition thereof, and usage thereof. Use of a humanized anti-Abeta antibody for the preparation of drugs for the treatment of a disease or disorder (such as Alzheimer's disease) caused by amyloid beta protein.

Anti-Aβ antibodies and antigen-binding fragments thereof

The present disclosure relates to a CD3 antibody and a pharmaceutical use thereof. Specifically, the present disclosure relates to forming a multi-specificity antibody by using CD3 antibody and binding molecules of another target. The multi-specificity antibody may simultaneously bind to CD3 and another tumor-associated antigen, and bind and activate CD3-positive T cells while binding tumor-associated antigen-expressing cells, thereby promoting T cells specifically killing tumor cells that express tumor-associated antigens. In addition, the present disclosure also provides a preparation and application of a multi-specific antibody.

CD3 antibody and pharmaceutical use thereof

Provided are an IL-5 antibody, an antigen binding fragment thereof, and a medical application therefor. The present invention comprises a mouse-derived antibody containing an IL-5 antibody CDR region, a chimeric antibody, a humanized antibody, and a pharmaceutical composition comprising said IL-5 antibody and said antigen binding fragment thereof, as well as the use of the pharmaceutical composition as a drug.

IL-5 antibody, antigen binding fragment thereof, and medical application therefor

The present invention relates to anti-PD-1 antibodies and antigen-binding fragments, and use of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.

Anti-PD-1 antibodies

Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.

Anti-PD-1/LAG3 bispecific antibodies

Growing community of inventors

Shanghai, China

Hua Ying